Drug Patents owned by Eli Lilly And Co
1. Drug name - AXIRON
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8784878 | ELI LILLY AND CO | Transdermal delivery rate control using amorphous pharmaceutical compositions |
Jul, 2023
(9 months from now) | |
| US8993520 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(3 years from now) | |
| US9180194 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(3 years from now) | |
| US8419307 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(4 years from now) | |
| US8807861 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(4 years from now) | |
| US9289586 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(4 years from now) | |
| US8435944 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Sep, 2027
(5 years from now) | |
Drugs and Companies using TESTOSTERONE ingredient
Treatment: A method of transdermally delivering testosterone; A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of increasing the testosterone blood level of a person in need thereof; A method of transdermal administration of a physiologically active agent to a subject.
Dosage: SOLUTION, METERED;TRANSDERMAL
| Strength | Dosage | Availability |
|---|---|---|
| 30MG/1.5ML ACTUATION | SOLUTION, METERED;TRANSDERMAL | Discontinued |
2. Drug name - BAQSIMI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10213487 | ELI LILLY AND CO | Nasal powder formulation for treatment of hypoglycemia |
Feb, 2036
(13 years from now) | |
| US10894133 | ELI LILLY AND CO | Device for dispensing a fluid product |
Jan, 2038
(15 years from now) | |
| US10765602 | ELI LILLY AND CO | Medication delivery systems and methods |
Sep, 2039
(17 years from now) | |
Drugs and Companies using GLUCAGON ingredient
Treatment: Treatment of severe hypoglycemia in patients with diabetes
Dosage: POWDER;NASAL
| Strength | Dosage | Availability |
|---|---|---|
| 3MG | POWDER;NASAL | Prescription |
3. Drug name - OLUMIANT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8158616 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Jun, 2030
(7 years from now) | |
| CN103788098A | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitor |
May, 2016
(6 years ago) | |
| CN102026999A | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| CN102026999B | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitor |
Mar, 2029
(6 years from now) | |
| IN270765B | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| IN201001863P3 | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| EP2288610A1 | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| EP2288610B8 | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| EP2288610B1 | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420629 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(6 years from now) | |
Drugs and Companies using BARICITINIB ingredient
Treatment: Treatment of rheumatoid arthritis
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1MG | TABLET;ORAL | Prescription |
| 2MG | TABLET;ORAL | Prescription |
4. Drug name - REYVOW
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7423050 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Apr, 2025
(2 years from now) | |
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(15 years from now) | |
| CN100352817C | ELI LILLY AND CO | As |
Mar, 2023
(5 months from now) | |
| CN1642939A | ELI LILLY AND CO | As |
Mar, 2023
(5 months from now) | |
| IN238831B | ELI LILLY AND CO | A Substituted Pyridinoylipieridines Compound As 5-Ht If Agonists |
Mar, 2023
(5 months from now) | |
| IN200401392P2 | ELI LILLY AND CO | Pyridinoylpiperidines As 5-Ht1F Agonists |
Mar, 2023
(5 months from now) | |
| EP1492786B1 | ELI LILLY AND CO | Pyridinoylpiperidines As 5-Ht1F Agonists |
Mar, 2023
(5 months from now) | |
| EP1492786A1 | ELI LILLY AND CO | Pyridinoylpiperidines As 5-Ht1F Agonists |
Mar, 2023
(5 months from now) | |
| EP3551617A1 | ELI LILLY AND CO | Compositions And Methods Related To Pyridinoylpiperidine 5-Ht1F Agonists |
Dec, 2037
(15 years from now) | |
| EP3551617B1 | ELI LILLY AND CO | Compositions And Methods Related To Pyridinoylpiperidine 5-Ht1F Agonists |
Dec, 2037
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748459 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Mar, 2023
(5 months from now) | |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
Treatment: Acute treatment of migraine
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 50MG BASE | TABLET;ORAL | Prescription |
| EQ 100MG BASE | TABLET;ORAL | Prescription |
| EQ 200MG BASE | TABLET;ORAL | Discontinued |
5. Drug name - VERZENIO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7855211 | ELI LILLY AND CO | Protein kinase inhibitors |
Dec, 2029
(7 years from now) | |
| CN102264725A | ELI LILLY AND CO | Protein Kinase Inhibitor |
Dec, 2029
(7 years from now) | |
| CN102264725B | ELI LILLY AND CO | Protein Kinase Inhibitors |
Dec, 2029
(7 years from now) | |
| IN297760B | ELI LILLY AND CO | Protein Kinase Inhibitors |
Dec, 2029
(7 years from now) | |
| IN201103454P4 | ELI LILLY AND CO | Protein Kinase Inhibitors |
Dec, 2029
(7 years from now) | |
| EP2379528B1 | ELI LILLY AND CO | Protein Kinase Inhibitors |
Dec, 2029
(7 years from now) | |
| EP2379528A1 | ELI LILLY AND CO | Protein Kinase Inhibitors |
Dec, 2029
(7 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 50MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
| 150MG | TABLET;ORAL | Prescription |
| 200MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.